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Colorectal cancer (CRC) is the third most common type of cancer 
globally, with over 1.8 million cases diagnosed in 2018. Incidence of 
CRC increases with age, and peak rates of new diagnoses occur in 
those aged 85– 89. Furthermore, CRC accounts for the second high-
est number of deaths due to cancer. (CRUK, 2014).
Over the last forty years, technological advancements have en-
hanced detection and treatment for CRC, leading to improvements 
in survival and mortality rates (CRUK, 2014). In conjunction with the 
ageing population, the number of people living with and surviving 
cancer is expected to increase. In this way, CRC is increasingly con-
sidered a chronic condition, requiring care that stems beyond the 
initial phases of diagnosis and treatment.
The economic impact of better diagnosis, increasing lines of 
available treatment and improved survival is far reaching. Not only 
are there direct monetary implications for health and care service 
providers in terms of detection, treatment and follow- up care of 
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Abstract
Introduction: Several forces are contributing to an increase in the number of people 
living with and surviving colorectal cancer (CRC). However, due to the lack of available 
data, little is known about the implications of these forces. In recent years, the use of 
administrative records to inform research has been increasing. The aim of this paper 
is to investigate the potential contribution that administrative data could have on the 
health economic research of CRC.
Methods: To achieve this aim, we conducted a systematic review of the health eco-
nomic CRC literature published in the United Kingdom and Europe within the last 
decade (2009– 2019).
Results:  Thirty- seven relevant studies were identified and divided into economic 
evaluations, cost of illness studies and cost consequence analyses. Conclusions: The 
use of administrative data, including cancer registry, screening and hospital records, 
within the health economic research of CRC is commonplace. However, we found 
that this data often come from regional databases, which reduces the generalisability 
of results. Further, administrative data appear less able to contribute towards under-
standing the wider and indirect costs associated with the disease. We explore several 
ways in which various sources of administrative data could enhance future research 
in this area.
K E Y WO RD S
administrative data, bowel cancer, colorectal cancer, costs, health economic research, 
systematic review
2 of 16  |     LEMMON Et aL.
CRC, but also there are indirect implications for patients, their fami-
lies and wider society in terms of the impact of CRC on labour force 
participation and on both physical and mental well- being. It is crucial 
that we can measure these implications in order to assess the impact 
of CRC and to help inform policymakers decisions on how best to 
allocate a finite health budget.
The current availability of data to inform this understanding is 
somewhat limited and more often than not, data from clinical trials are 
used to make assumptions about the possible impact of an interven-
tion on the entire population and ultimately inform decisions about 
resource allocation. Unfortunately, the generalisability of efficacy and 
cost- effectiveness measures from clinical trials to real- life populations 
can be limited by sample selection, size and attrition (He et al., 2020; 
Leon et al., 2006). Furthermore, clinical trials can be expensive to im-
plement and run and often have short follow- up periods, meaning that 
longer term outcomes cannot be observed (Fitzpatrick et al., 2018).
One potential solution to the issue of the generalisability of trial 
data to whole populations lies in the use of administrative data. That 
is, data that are collected routinely ‘by government departments and 
other organisations for the purposes of registration, transaction and 
record keeping, usually during the delivery of a service’ (Woollard, 
2014). Examples include hospital admissions data, education records 
and tax records. The routine collection of administrative data pres-
ents an exciting opportunity to conduct population level research 
that offers insights into healthcare resource use, costs and outcomes 
across a variety of domains such as education, income and retire-
ment, through the linkage of these records to other data sets includ-
ing clinical trials (Card et al., 2010; Einav & Levin, 2014; Fitzpatrick 
et	al.,	2018).	Moreover,	administrative	data	can	overcome	the	short	
follow- up period inherent in trials by tracking individuals over time, 
for example as they move in and out of hospital, into long- term care 
and even up to the end of their lives.
Despite these advantages, since administrative data are not 
generated for research purposes, they often lack the usual auxil-
iary measures that are used in social research to draw causal infer-
ence from a data set (Connelly et al., 2016). Thus, one of the central 
prospects for administrative data is for its use as a complementary 
source of information alongside clinical trials and survey data. The 
benefits of linking administrative records to observational data are 
documented elsewhere (Doiron et al., 2013).
Over the years, the potential of administrative data in research 
has been recognised worldwide and efforts have been made to 
harness that potential (Card et al., 2010; Einav & Levin, 2014). In 
the Nordic countries in particular, robust data sharing infrastruc-
tures have been developed to facilitate researchers in making use 
of	 administrative	 data	 sets	 (Connelly	 et	 al.,	 2016).	 Moreover,	 the	
linkage aspect of administrative data has led to large data reposito-
ries emerging, where data sets are linked together and researchers 
can apply to access specific data sets and cohorts, to carry out their 
analysis (Doiron et al., 2013). Further, data repositories enhance 
research transparency because their indefinite storage allows for 
the replication of results. The success of such repositories has been 
made clear, for example the Western Australia Data Linkage System 
(WADLS) repository includes over 30 population- based data sets 
and has produced over 250 journal publications (Doiron et al., 2013).
Of course, the creation of such repositories is not without its 
challenges. In particular, any research project that uses personal 
health data where informed consent is not obtained from patients 
may pose a risk to individual privacy. Therefore, central to the cre-
ation of a research repository is striking the appropriate balance 
between public benefit and patient privacy. That means being clear 
and transparent about the purposes of the research and its potential 
to generate patient or public benefit, at the same time taking mea-
sures to minimise the risk to patient privacy for example through the 
pseudonymisation or anonymisation of data.
We have identified that Scotland is in a unique position to demon-
strate the potential contribution of administrative data, as well as an 
administrative data repository, within the health economic research of 
CRC. This is primarily due to the current data sharing and linkage infra-
structure. Specifically, all Scottish residents have a unique Community 
Heath Index (CHI) number that permits the linkage of their administra-
tive health records to one another and to other data sets.
The overarching aim of this paper is to investigate the potential 
contribution that administrative data could have on health economic 
research of CRC. To achieve this aim, the objectives were as follows:
1. To summarise the existing health economic research of CRC 
in the UK and Europe;
2. To identify whether and what types of administrative data were 
used within this research;
3. To explore the benefits and limitations of using administrative 
data in this research;
4. To discuss the ways in which administrative data, using Scotland 
as an exemplar, could contribute to this research in the future.
In what follows we outline the methods employed for the sys-
tematic review. Section 3 presents the results, and Section 4 dis-




English language articles published between 2009 and 2019. 
Specifically, our aim was to identify health economic research articles 
which focussed on CRC. To achieve this aim, we included those articles 
where the words ‘colorectal cancer’ or ‘bowel cancer’ appeared in the 
title and where both ‘economic’ and ‘cost’ appeared in the abstract.1
A Google Scholar search was also conducted to capture other 
relevant	articles.	We	followed	the	PRISMA	guidelines	where	appli-
cable	for	conducting	this	review	(PRISMA,	2020).
 1The search strategy was as follows: 1.(Colorectal cancer OR bowel cancer).title AND 
economic.abstract and cost.abstract. 2. Limit 1 to (English language AND year 
="2009– 2019").
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2.2  |  Selection criteria
Full- text publications of health economic studies were included 
when available in English language. The definitions of health eco-
nomic studies are outlined in Table 1. Articles that were not carried 
out in Europe or the UK were excluded. Further, review articles were 
also excluded.
2.3  | Data extraction
The articles were grouped into the study groups as outlined in 
Table 1. A proforma was used to extract the relevant data from 
each article within these groups. For all types of studies, the 
country, perspective taken, method employed, data sources 
used (including administrative data), types of costs included, 
TABLE  1 Definition	of	health	economic	studies	included	in	final	review
Study Description
Budget Impact Analysis (BIA) Budget impact analyses assess the affordability of a novel healthcare intervention or policy change 
applied to a specific healthcare budget, at an aggregate population level.
Cost Comparison (Cost 
Minimisation)	(CC)
CC is a method of comparing the costs of two or more interventions when the health outcomes of the 
interventions are assumed to be the same.
Cost of Illness (Burden of Illness)
(COI)
COI studies attempt to quantify the costs of a specific disease. This might be for the entire disease 
pathway or for parts of it. Unlike EEs, they do not attempt to compare costs for competing 
interventions rather, they provide an estimate of the cost given the existing provision of care.
Economic Evaluation Economic evaluation aims to calculate the costs and benefits of an intervention or treatment, in order to 
establish whether it is cost effective and thus inform investment in services. There are four main types 
of economic evaluation, which differ in terms of how they measure outcomes:
Cost Benefit Analysis (CBA) In CBA, health outcomes are measured in monetary units.
Cost- Effectiveness Analysis (CEA) In CEA, outcomes are measured in natural or health units such as life years gained or cancers detected.
Cost Utility Analysis (CUA) CUA is a special type of CEA in which outcomes are measured in preference based health outcomes such 
as Quality Adjusted Life Years (QALY).
Source: Adapted from York Health Economics Consortium Glossary (York Health Economics Consortium, 2016)
F IGURE  1 Literature	search	results
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costs data sources used and the part of the CRC pathway under 
study were extracted. For the EEs, the type of evaluation was 
also noted.
Figure	1	below	outlines	the	PRISMA	(PRISMA,	2020)	flow	dia-
gram of the search strategy results.
3  |  RESULTS
3.1  |  Literature search results
The articles were almost equally split between EEs (n = 19, 51%) and 
costing studies (n = 18).
As per Table 1, the costing studies were categorised into Cost of 




Tables 2, 3 and 4 present the EEs, COI and CCs included in the final 
review.
Around 47% (n = 9) of the EEs were conducted in the UK and the 
majority (68%) of EEs conducted a CUA, whilst the remainder chose 
to implement a CEA. As is standard within an EE framework, the 
majority	of	studies	accompany	their	EE	with	a	decision	tree,	Markov	
model or simulation model, in order to extrapolate CRC costs and 
outcomes over time, for example up until the end of life.
In EE, it is standard practice to explicitly state the perspective 
of the evaluation. Of the 19 EE’s identified, 53% (n = 10) take a 
healthcare system perspective. Other perspectives taken include a 
healthcare payer perspective, health insurance perspective or soci-
etal perspective.
TABLE  2 UK/EU	Economic	Evaluations,	n	=	19
Reference Country Perspective Evaluation Method Data Sources Admin Data Costs Data Sources: Costs Pathway
Arrospide et al., (2018) Basque Healthcare system CUA, BIA Semi-	Markov	microsimulation Screening data, cancer registry, 
national statistics
Yes Direct Accounting system Screening- end of life
Atkin et al., (2017) UK Health and social care system CUA Patient level simulation Hospital records, previous studies, 
life tables
Yes Direct National tariffs Surveillance- end of life
Asseburg et al., (2011) Germany Health insurance perspective CEA Patient level simulation Previous studies, expert opinion Yes (costs only) Direct National tariffs, market prices Treatment - 10 years post
Bullement et al., (2018) England/Wales Healthcare system CEA, CUA Partitioned survival model Previous studies Yes (costs only) Direct Market	prices,	national	tariffs,	
previous study
Treatment- end of life
Halligan et al., (2015) England Healthcare system- secondary care CEA Descriptive Primary data collection Yes Direct National tariffs, BNF Diagnosis−5	years	post
Kearns et al., (2014) England Health and social care system CEA, CUA Markov	model Previous studies, screening data Yes Direct Previous study Screening- end of life
Lansdorp- Vogelaar et al. 
(2018)
Netherlands Societal perspective CEA Semi-	Markov	microsimulation Previous studies, life tables No Direct & indirect Previous studies Screening- end of life
Matter-	Walstra	et	al.,	(2016) Switzerland Healthcare system CEA Descriptive, regression Previous study No Direct Primary data collection Treatment (and overall 
survival)
Michalopoulos	et	al.,	(2013) Greece Not stated CUA Descriptive, regression Primary data collection No Direct Primary data collection Surgery
Murphy	et	al.,	(2017) England Healthcare system CUA, BIA Markov	model Previous studies, life tables Yes (costs only) Direct National tariffs, screening data, 
previous study
Screening- end of life
Pil et al., (2016) Belgium Societal perspective CUA, BIA Decision	tree	&	Markov	model Previous studies, cancer registry, 
screening data, national 
statistics
Yes Direct & indirect Official Belgian costs of medical 
procedures, previous studies
Screening - 50 years post
Pilgrim et al., (2009) England Not mentioned CUA Discrete event simulation Previous studies, hospital records, 
expert opinion
Yes Direct National tariffs, previous studies Screening- end of life
Rao et al., (2018) UK Healthcare system CUA Decision	tree	&	Markov	model Previous studies, hospital records, 
life tables
Yes Direct National tariffs Treatment- end of life
Rautenberg et al., (2014) Germany Health insurance perspective CEA Descriptive Previous studies No Direct Market	prices Treatment
Robles- Zurita et al., (2018) UK2 Health and social care system CUA Partitioned survival model Previous study Yes (costs only) Direct National tariffs, primary 
collection
Treatment- 8 years post
Sobhani et al., (2011) France Healthcare payer CUA Markov	model Previous studies, national statistics No Direct Previous studies Screening - end of life
Tilson et al., (2012) Ireland Healthcare payer CEA Decision tree model Previous studies, cancer registry, 
hospital records, expert opinion
Yes Direct National tariffs, previous studies, 
hospital finance department
Diagnosis−5	years	post
van	der	Meulen	et	al.,	(2018) Netherlands Third party payer CUA Semi-	Markov	microsimulation Previous studies, life tables No Direct Previous study Screening- end of life
Whyte et al., (2012) England Health care system CUA State	Transition	Model Previous studies, screening data, 
expert opinion
Yes Direct National tariffs, previous study Screening- end of life
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The perspective taken influences the types of costs that are in-
cluded. As a result, the vast majority (89%) of studies only include 
direct costs associated with the delivery of care. The two studies 
which take a societal perspective, Lansdorp- Vogelaar et al., (2018) 
and Pil et al., (2016), also incorporate indirect costs, that is additional 
costs encountered by the patients such as loss of earnings. In terms 
of which part of the CRC pathway is investigated, the most common 
evaluations are conducted on screening programmes. In particular, 
45% (n = 9) of the included studies evaluate the cost- effectiveness 
of different CRC screening programmes. A further 40% (n = 7) look 
at the cost- effectiveness of treatment for CRC, including curative 
treatment and treatment for metastatic disease. A smaller propor-
tion of the EE’s, 10% (n = 2), look at diagnosis and 5% (n = 1) at surveil-
lance	of	adenomas.	As	most	studies	use	Markov	and	microsimulation	
models, they tend to model outcomes and costs beyond the initial 
pathway starting point, either until the end of life or an alternative 
long- term end point, for example 50 year follow- up. In addition to 
conducting a CUA to assess the value of a healthcare intervention, 
three of the EEs conducted a budget impact analysis (BIA) to assess 
the affordability of the intervention for a specific healthcare budget 
(Arrospide	et	al.,	2018;	Murphy	et	al.,	2017;	Pil	et	al.,	2016).
In contrast to the evaluations, only 31% (n = 4) of the COI articles 
identified were UK based (England only). Ireland accounted for al-
most a quarter of the studies (n = 3), followed by Italy (n = 2), France 
(n = 2) and Spain (n = 2). The majority of COI articles conducted ret-
rospective cohort analyses (77%). This involves looking at historical 
data to identify a cohort of patients, for example those with meta-
static CRC, and costing their use of healthcare resources.
In addition, COI studies were less likely to mention which per-
spective the analysis is conducted from. However, like EEs, the COI 
studies tended to focus on direct costs. Only two COI papers looked 
solely at indirect costs (Hanly et al., 2013; ÓCéilleachair et al., 2017) 
and one included both direct and indirect costs (Lejeune et al., 2009). 
With respect to the particular part of the CRC care pathway costed, 
TABLE  2 UK/EU	Economic	Evaluations,	n	=	19
Reference Country Perspective Evaluation Method Data Sources Admin Data Costs Data Sources: Costs Pathway
Arrospide et al., (2018) Basque Healthcare system CUA, BIA Semi-	Markov	microsimulation Screening data, cancer registry, 
national statistics
Yes Direct Accounting system Screening- end of life
Atkin et al., (2017) UK Health and social care system CUA Patient level simulation Hospital records, previous studies, 
life tables
Yes Direct National tariffs Surveillance- end of life
Asseburg et al., (2011) Germany Health insurance perspective CEA Patient level simulation Previous studies, expert opinion Yes (costs only) Direct National tariffs, market prices Treatment - 10 years post
Bullement et al., (2018) England/Wales Healthcare system CEA, CUA Partitioned survival model Previous studies Yes (costs only) Direct Market	prices,	national	tariffs,	
previous study
Treatment- end of life
Halligan et al., (2015) England Healthcare system- secondary care CEA Descriptive Primary data collection Yes Direct National tariffs, BNF Diagnosis−5	years	post
Kearns et al., (2014) England Health and social care system CEA, CUA Markov	model Previous studies, screening data Yes Direct Previous study Screening- end of life
Lansdorp- Vogelaar et al. 
(2018)
Netherlands Societal perspective CEA Semi-	Markov	microsimulation Previous studies, life tables No Direct & indirect Previous studies Screening- end of life
Matter-	Walstra	et	al.,	(2016) Switzerland Healthcare system CEA Descriptive, regression Previous study No Direct Primary data collection Treatment (and overall 
survival)
Michalopoulos	et	al.,	(2013) Greece Not stated CUA Descriptive, regression Primary data collection No Direct Primary data collection Surgery
Murphy	et	al.,	(2017) England Healthcare system CUA, BIA Markov	model Previous studies, life tables Yes (costs only) Direct National tariffs, screening data, 
previous study
Screening- end of life
Pil et al., (2016) Belgium Societal perspective CUA, BIA Decision	tree	&	Markov	model Previous studies, cancer registry, 
screening data, national 
statistics
Yes Direct & indirect Official Belgian costs of medical 
procedures, previous studies
Screening - 50 years post
Pilgrim et al., (2009) England Not mentioned CUA Discrete event simulation Previous studies, hospital records, 
expert opinion
Yes Direct National tariffs, previous studies Screening- end of life
Rao et al., (2018) UK Healthcare system CUA Decision	tree	&	Markov	model Previous studies, hospital records, 
life tables
Yes Direct National tariffs Treatment- end of life
Rautenberg et al., (2014) Germany Health insurance perspective CEA Descriptive Previous studies No Direct Market	prices Treatment
Robles- Zurita et al., (2018) UK2 Health and social care system CUA Partitioned survival model Previous study Yes (costs only) Direct National tariffs, primary 
collection
Treatment- 8 years post
Sobhani et al., (2011) France Healthcare payer CUA Markov	model Previous studies, national statistics No Direct Previous studies Screening - end of life
Tilson et al., (2012) Ireland Healthcare payer CEA Decision tree model Previous studies, cancer registry, 
hospital records, expert opinion
Yes Direct National tariffs, previous studies, 
hospital finance department
Diagnosis−5	years	post
van	der	Meulen	et	al.,	(2018) Netherlands Third party payer CUA Semi-	Markov	microsimulation Previous studies, life tables No Direct Previous study Screening- end of life
Whyte et al., (2012) England Health care system CUA State	Transition	Model Previous studies, screening data, 
expert opinion
Yes Direct National tariffs, previous study Screening- end of life
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there was considerable variation within the COI studies. Three looked 
at the pathway from diagnosis to end of life (Bending et al., 2010; 
Corral et al., 2016; Francisci et al., 2013). Others focussed on diagno-
sis, but only looked at costs from diagnosis up to a pre- specified time 
point, for example 12 months postdiagnosis or within 12 months of 
initial diagnosis. Two studies looked at all hospital care throughout 
the	care	pathway	(Laudicella	et	al.,	2016;	Macafee	&	Whynes,	2009).	
One study focussed on treatment of metastatic and non- metastatic 
disease	up	until	the	end	of	life	(Mar	et	al.,	2017),	whilst	another	fo-
cussed on costs of treating metastatic disease alone (Giuliani et al., 
2012). Similarly, one study looked at the cost of surgery alone (Jean- 
Claude et al., 2012)and another at the costs from surgery up to three 
years post- surgery (Lejeune et al., 2009). One COI study also con-
ducted a BIA for patients who underwent CRC surgery in French non- 
profit hospitals (Jean- Claude et al., 2012).
Of the CC studies identified in Table 4, two of the CC studies 
are from Italy and the remaining three are from Greece, Sweden and 
Germany. As with the COI studies, the predominant methodology ap-
plied in the CCs is a retrospective cohort approach. In terms of the 
perspective, the majority of the CC studies conduct their analyses 
from the perspective of the health system in which they are based. 
One of the studies takes the perspective of the healthcare payer, and 
another takes both a health policymaker and a societal perspective. 
Once again, the focus on costs is mainly on direct costs; however, two 
CC papers also incorporate indirect costs. The majority of CC studies 
focus on the treatment part of the CRC pathway. One paper focusses 




The papers identified use a mixture of data sources including ad-
ministrative data, national statistics, previous studies including 
randomised control trials (RCTs), expert opinion and in some cases 
primary data collection. Table 5 below outlines the administrative 
data sources that appeared most frequently in the studies. In addi-
tion, Tables 6, 7 and 8 in the appendix provide a broader overview of 
the various data sources used to inform the main groups of param-
eters included in the literature.
Within the EEs, 68% (n = 13) utilise administrative data. The 
most common use of administrative data within these studies 
is via the use of administrative costs data bases to calculate di-
rect costs (those which relate directly to patient care such as a 
hospital stay). Further, some studies use administrative data, for 
example cancer registry, to inform particular patient and clinical 
parameters	in	the	decision	trees,	Markov	and	simulation	models.	
Of the EEs which use administrative data, five evaluate screening 
programmes and use administrative screening programme data in 
their analysis. This clearly reflects the effort in many European 
countries in recent years to detect cancer as early as possible 
for those at the highest risk by rolling out national screening 
programmes for CRC. As a result, a multitude of administrative 
screening data sets have been created and researchers have capi-
talised on this opportunity.
It is also common for those studies to combine the screening 
data with other administrative data sets. In particular, Arrospide 
et al., (2018) combine data from the Basque screening programme 
with cancer registry data to evaluate the Basque CRC screening 
programme. Pil et al., (2016) use data from the Belgian government 
screening programme alongside the Belgian cancer registry in their 
analysis of a population- based CRC screening programme. Finally, in 
their evaluation of different surveillance strategies for patients with 
intermediate- grade adenomas, Atkin et al., (2017) use routine hospi-
tal records together with data from the English bowel cancer screen-
ing	pilot.	In	the	three	EEs	(Arrospide	et	al.,	2018;	Murphy	et	al.,	2017;	
Pil et al., 2016) who undertook BIAs, location- specific estimates of 
population size, age- specific disease incidence, resource use and 
location- specific costs were acquired from various administrative 
TABLE  5 Administrative	data	sources
Data source Description
Cancer registry data Cancer registries contain a record of all cases of new cancer diagnoses in one centralised system. They tend 
to include information on cancer diagnoses and treatment, allowing a country to monitor cancer incidence 
and survival, and any emerging trends, over a long period of time. Registries also include patient level 
demographics, permitting analyses of diagnoses by age, gender and stage distribution. They can also include 
information on cancer related mortality.
Screening programme data Screening programme data sets provide a wealth of information including participation and compliance rates, 
adenoma and CRC detection rates, specificity and sensitivity, as well as information on surveillance. In some 
cases, follow- up data are also available, for example on colonoscopies and flexible sigmoidoscopy. Follow- up 
data provide information on participation, detection and complications.
Routine hospital records Routine hospital records provide information on any acute hospital admission experienced by a patient, including 
length	of	stay	and	procedure	codes.	Moreover,	hospital	records	often	include	additional	information	about	an	
individuals primary and secondary diagnoses, allowing the researcher to gather more information about patient 
co- morbidity and other procedures and medications related to or unrelated to their cancer diagnosis.
Costs databases Administrative costs data are collected in the form of national tariffs for the reimbursement of the provision of 
hospital services and in hospital accounting systems. These systems are usually updated annually and therefore 
provide robust and up to date estimates of unit costs for economic analyses.
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data sources to permit analyses that were relevant and useful to the 
budget holder in question.
At the same time, the extent to which administrative data are 
used within the EEs varies considerably and no one study relies 
exclusively on routine data. For example, Atkin et al., (2017) use 
routine hospital records linked to cancer registry data to inform 
many of the parameters in their patient level simulation model, 
whilst Rao et al., (2018) use routine hospital records solely for the 
purposes of informing their parameter on postoperative mortal-
ity. Furthermore, several EEs use administrative costs data only 
(Asseburg	et	al.,	2011;	Bullement	et	al.,	2018;	Murphy	et	al.,	2017;	
Robles- Zurita et al., 2018). In every EE, the existing literature or 
previous RCTs are also used to inform specific model parameters. 
Where this is the case, it is possible that the prior research also used 
administrative data.
The COI studies utilise administrative data more often compared 
to the EEs. In particular, 11 of the 12 COI papers identified in Table 3 
use administrative data. In comparison with the EE’s, where much 
of the administrative data comes from screening programmes, the 
main sources of administrative data in the COI studies come from 
cancer registries and routine hospital records. In the majority of 
cases, the COI studies use cancer registry data to identify a cohort 
of patients to be analysed. The registry data provide clinical informa-
tion on CRC diagnosis, staging, location of tumour, date of diagnosis 
etc. This information is then linked to routine hospital records that 
contain information on treatment, co morbidities, complications and 
recurrence etc.
In addition to using cancer registries and clinical information 
systems to analyse CRC cohorts, several COI studies use registry 
data as a means of identifying patients to invite them to partici-
pate in a survey or interview. Specifically, Hanly et al., (2013) and 
ÓCéilleachair et al., (2017) use Irish cancer registry data to identify 
individuals with primary, invasive CRC in order to invite them to 
complete postal questionnaires. Survey responses are then com-
bined with clinical information from the cancer registry to conduct 
statistical analysis. Similarly, ÓCéilleachair et al., (2012) used hospi-
tal records from six participating sites to identify patients who would 
be eligible to take part in interviews for their qualitative analysis of 
the inter- relationships between the economic and emotional conse-
quences of CRC.
Like EE’s, COI studies often utilise administrative costs data 
bases to calculate direct costs. Only one study used administrative 
data to inform the calculation of indirect costs (those costs that 
occur outside the delivery of patient care, such as lost productivity 
or foregone wages). Specifically, Lejeune et al., (2009) use hospital 
records data to measure the distance travelled to and from the pa-
tients home to consult with their GP or gastroenterologist, which 
was then used to calculate indirect costs to the patient.
Overall, compared to EEs, COI studies are more likely to rely ex-
clusively on administrative data (Corral et al., 2016; Francisci et al., 
2013; Giuliani et al., 2012; Laudicella et al., 2016; Lejeune et al., 
2009;	Macafee	&	Whynes,	2009;	Mar	et	al.,	2017)	and	are	far	less	
likely to use previous studies to inform parameters.
Finally, almost all of the CC studies use administrative data of 
some sort. As with the EEs, some use administrative data in the form 
of costs databases only and like the COI studies some use adminis-
trative hospital records.
4  | DISCUSSION AND CONCLUSION
Clearly, one area in which administrative data have been particularly 
powerful is in evidence on the cost- effectiveness of various screen-
ing strategies for CRC, which has resulted from the evolution of na-
tional screening programmes throughout Europe. Data from these 
programmes have been used to inform and update many of the cru-
cial parameters used in the models that accompany EEs of screening 
programmes. This evidence base invariably demonstrates the feasi-
bility and potential of collecting administrative data on this scale to 
inform other parts of the treatment pathway for CRC.
At the same time, administrative cancer registry data have 
proved to be useful in terms of defining and identifying cohorts 
for costing studies and again for informing vital parameters such as 
disease	prevalence,	 treatment	and	outcomes.	Many	EE’s	have	also	
taken advantage of the power of data linkage by linking administra-
tive records to data form participants in RCTs.
Furthermore, since providing estimates of costs is central to con-
ducting both EE’s and costing analyses, the emergence of costs da-
tabases have proved to be a valuable source of information on costs 
for all areas of economic research into CRC. Specifically, 43% (n=16) 
of the studies identified used administrative costs databases.
The administrative costs databases have proved particularly 
powerful in the studies that include direct costs. In particular, the 
costing approaches implemented in those papers are consistent with 
the existence of European Disease Related Group (DRG) type sys-
tems for reimbursing hospitals for their services. Therefore, unsur-
prisingly, many of them implement a ‘top- down’ costing approach by 
using national tariffs based on DRGs to attach monetary values to 
patients resource utilisation (Špacírová et al., 2020). This highlights 
the potential for administrative data to contribute to understanding 
the costs of delivering CRC care.
Finally, the merit of using administrative data for the purposes of 
BIA is clear. In an era of increasing austerity and budget cuts, using 
administrative data within BIAs to more accurately predict the af-
fordability of introducing novel interventions into a fixed budget 
healthcare system will ensure more efficient allocation of resources. 
Using locally or nationally collected administrative data for the pur-
poses of BIA is particularly useful because this will make any analysis 
more relevant and useful to the budget holder in question.
Having said that, we have identified some areas where the use 
of administrative data has been limited. For example, although one 
of the main advantages of using routine records in research is their 
ability to capture large populations over long periods of time, we 
find little evidence that this is the case for the health economics 
literature on CRC. Specifically, only one costing study used routine 
records to capture an entire population over a long period of time 
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(Laudicella et al., 2016). Excluding this example, the maximum sam-
ple size identified is less than a few thousand and in most cases, 
the populations under study come from a single hospital or ad-
ministrative area. At the same time, many of the costing studies 
identified look at one specific part of the disease pathway with a 
limited follow- up period. Overall, it appears that the power of ad-
ministrative data to provide evidence for whole populations, span-
ning the entire disease pathway and follow- up for survivors, is yet 
to be harnessed.
Related to this, we found a lack of evidence on the wider costs 
associated with CRC, particularly with respect to social care and in-
direct costs such as unpaid care. For example, although evidence 
shows that many cancer patients need social care as a direct con-
sequence of their condition and the consequences of its treatment, 
none of the papers identified look at the use of social care services 
by	CRC	patients	(MacMillan	Cancer	Support,	2015).
Furthermore, few papers explored indirect costs. In particular, 
only two EEs explicitly take a societal perspective and therefore in-
clude both direct and indirect costs of care (LansdorpVogelaar et al., 
2018; Pil et al., 2016). Within the COI studies, Hanly et al., (2013) and 
ÓCéilleachair et al., (2017) focus exclusively on indirect costs, whilst 
Lejeune et al., (2009) include direct and indirect costs. Further, the 
CC’s	carried	out	by	Maniadakis	et	al.,	(2009)	and	Tscheulin	and	Drevs	
(2010) also include both direct and indirect costs. The lack of inclu-
sion of indirect costs overall is not surprising given that they are no-
toriously difficult to measure. However, of those who did, the use of 
administrative data was even less likely. Clearly, measuring indirect 
costs is challenging in itself, but in addition to this, the administrative 
data appear less able to contribute to studies which include the in-
direct costs of CRC. This highlights a key limitation of administrative 
records in their ability to capture indirect costs.
Finally, it appears that administrative data are less able to con-
tribute when it comes to measuring patient health related quality 
of life (HRQoL) and preferences for those health states, which is 
vital particularly in EEs. None of the EEs used administrative data 
to inform utility parameters. In most cases, studies look to previous 
literature, often going back several years, for this information. As ad-
ministrative data are not collected for the purposes of research, it is 
not surprising that they lack the types of measures needed to capture 
patient outcomes in the way that is needed for EEs. Nonetheless, 
recent developments in tools to capture Patient Reported Outcome 
Measures	(PROMS)	on	symptoms,	condition	and	quality	of	life	might	
be	used	 to	measure	outcomes	 in	CRC	patients.	PROMS	will	add	a	
valuable patient- centred dimension to routine data sets, and plans 
are underway to collect this data in the future.
In summary, it is not uncommon for the health economic re-
search of CRC to utilise administrative records to aid EEs and costing 
analyses, and undoubtedly, they can offer a wealth of information 
about an individuals CRC diagnoses, subsequent treatment and fol-
low- up over time. However, there appear to be several limitations 
to their use and gaps in the existing evidence. In what follows, we 
consider how Scottish administrative data might mitigate those lim-
itations and fill in some of the gaps in the evidence.
As discussed in Section 1, Scotland is in a prime position to 
demonstrate the contribution of administrative data, in particular 
due to its data sharing and data linkage infrastructure. In theory, this 
infrastructure means that all health data sets can easily be linked to 
one another and to administrative data sets in other domains, for 
example social care.
In October 2018, the Public Benefit Privacy Panel for health 
and social care approved a project to link several administrative 
data sets for CRC patients in Scotland (Study numer: 1718- 0026), 
in order to conduct research into the economics of CRC. This proj-
ect is part of a wider Cancer Research UK funded project, Bowel 
Cancer Intelligence UK, which has been granted permission from the 
Research Ethics Service of the Health Research Authority for a CRC 
research data repository called COloRECTal Repository (CORECT- R) 
(BCIUK, 2021). The Scottish data provide a useful platform on 
which to demonstrate the possible contribution of administrative 
data and a CRC repository to the health economic research of CRC 
within the UK and Europe. A contribution that is enhanced by the 
similarities between data collection and data coding systems within 
the constituent UK nations and further afield, for example, the 
International Classification of Disease (ICD) and OPCS Classification 
of Interventions and Procedures (OPCS- 4). This provides the op-
portunity for research conducted in a Scottish CRC context to be 
replicated with similar linkages outside of Scotland. However, fur-
ther work will be required to harmonise data sets to allow for cross 




Furthermore, Scottish administrative data could contribute to 
the evidence by simply providing evidence for Scotland. Despite 
the wealth of administrative data sets and data infrastructure in 
existence in Scotland, there appears to be limited health econom-
ics research of CRC within the Scottish context. In particular, only 
two studies identified in this review used Scottish administrative 
records (Atkin et al., 2017; Robles- Zurita et al., 2018). In both stud-
ies, Scotland was represented alongside data from other countries. 
Thus, a Scottish CRC data repository would afford the opportunity 
for health economic research into CRC in Scotland to be realised.
In addition, the use of Scottish administrative data could be used 
to inform and update common model parameters used in both EEs 
and costing studies, using data that reflects current practice for 
an entire population, for example, prevalence and incidence rates, 
durations of treatments, survival outcomes etc. This information 
could not only be useful for other health economic studies of CRC in 
Scotland, but also for other nations in the UK and potentially other 
European countries who have similar demographics and health 
systems.
The data linkage infrastructure in Scotland would mean that all 
relevant health data sets can be linked to one another, in particular, 
cancer registry, cancer treatment, screening, outpatient and inpa-
tient, prescriptions, accident and emergency, GP data and more. This 
level of information would potentially capture the patients entire 
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CRC journey through the healthcare system, pre- and postdiagnosis, 
allowing for the more precise measurement of the key inputs into 
health economic studies of CRC. Furthermore, health data sets can 
also be linked to other administrative databases like social care and 
Department for Work and Pensions (DWP) data. These linkages to 
other administrative data sets outwith the healthcare system could 
provide additional information about a patients experience which 
could again be used to inform health economic research in this area, 
both within and outwith Scotland.
Finally, and related to the linkage opportunities, the use of 
Scottish administrative data could enhance the evidence base on 
other direct and indirect costs related to CRC. Specifically, the 
linkage to social care records could be particularly powerful in this 
respect. As highlighted earlier, none of the studies we identified 
looked at the use of longer term social care services by CRC pa-
tients, despite existing evidence showing that many cancer patients 
need social care as a direct consequence of their condition and the 
consequences	of	 its	treatment	 (MacMillan	Cancer	Support,	2015).	
In Scotland, local authorities are required to routinely collect infor-
mation on all social care services delivered to people within their 
area. This data could be used to provide evidence on other non- 
health related direct costs associated with CRC, again both during 
treatment and beyond. In addition, as part of the social care data 
collection, an indicator of the presence of an unpaid carer is col-
lected for social care clients. This information could be useful for 
understanding the indirect costs associated with a CRC diagnosis, 
in terms of the reliance on unpaid carers to provide additional care 
and support.
Going forward, it is important to recognise that there are ques-
tions administrative data cannot answer alone. In such cases, trial 
and survey data may fill the gaps, and vice versa. Specifically, clinical 
trial data offer the opportunity for randomisation, blinding and/or 
stratification, which allow assessment of the efficiency of new or ex-
isting treatments in a highly selected group of patients. In contrast, 
administrative data can play a unique role in testing the effective-
ness, in a real world setting, of treatments that have already been 
tested within trials. This sequence of events means that the types of 
questions that trial data set out to answer are likely to be different 
to those using administrative data. Overall, administrative data do 
not remove the need for trial or other data sources, instead these 
sources of data are complimentary.
That being said, we have found that the use of administrative 
data is common within the UK and EU health economic research on 
CRC. In particular, cancer registry, screening and routine hospital re-
cords were commonly used. In the EE’s, administrative data tended 
to be supplemented with data from the clinical trial under study and/
or from the existing literature. Costing studies were more likely to 
rely heavily on administrative records. Overall, we find that although 
administrative data are present, they do not appear to being used 
to their full potential and administrative data, including data reposi-
tories, within the UK and Europe could have a significant impact on 
research in this area. Scotland, in particular, may provide a valuable 
exemplar to unlock this potential.
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